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Introduction

Methotrexate (MTX) and 6-thioguanine (6-TG) are antimetabolites used both
singly and in combination for the treatment of various forms of leukemia and other
neoplasms (1,2).
investigated.

The

mechanism

of

action

of

MTX

has

been

extensively

By inhibition of the cellular enzyme, dihydrofolate reductase, MTX

causes a depletion of reduced folates which are necessary for a number of
biosynthetic reactions including de novo purine and thymidylic acid synthesis (1);
Figure 1 illustrates this effect.

In the cell this depletion of the thymidine and

purine deoxynucleotides leads to suppression of DNA synthesis and ultimately to
cell death.

If cells are provided with an exogenous source of purines such as

inosine or hypoxanthine and with exogenous thymidine, the cytotoxicity of MTX is
circumvented.

Another indirect metabolic consequence of MTX treatment is an

increase in the intracellular concentration of phosphoribosylpyrophosphate (PRPP)
due to the suppression of purine biosynthesis.

By itself, the expansion of PRPP

pools is of little consequence, but it can increase the rate of metabolism of other
molecules which utilize PRPP as a cofactor. In the case of 5-fluorouracil (FUra), a
cytotoxic agent which is activated by conversion of FUra to FUra-ribosephosphate
using

PRPP

and

©rotate

phosphoribosyltransferase,

pretreatment of cells with
enhanced cytotoxicity (3,4).

MTX

it

has

been

shown

that

leads to increased activation of FUra and

Thus MTX treatment, in addition to its inherent

toxicity, can metabolically increase the effectiveness of certain other agents
leading to synergistic cytotoxicity.
The mechanism of
converted

in

the

cell

6-TG toxicity is much less well established.
to

6-TG

ribosephosphate

(6-TGRP)

by

the

It is
enzyme

hypoxanthine-guanine phosphoribosyltransferase using PRPP as the cofactor; this

-
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conversion is apparently necessary for the cytotoxic action of 6-TG.

While

6-TGRP has been shown to inhibit a number of enzymes involved in purine
biosynthesis, it has been reported that the primary mechanism of cytotoxicity of
6-TG is via its incorporation into DNA (5).

Incorporation of 6-TG into RNA has

been reported, but no connection between this incorporation and cell toxicity has
been shown.

Since 6-TG, like FUra, is activated by reacting with PRPP(1,2), it

seemed possible that 6-TG and MTX might have a synergistic interaction analogous
to that already demonstrated between MTX and FUra.
The

present

study

characterizes

cytotoxic

and

metabolic

interactions

between MTX and 6-TG in L1210 mouse leukemia cells in culture. It is shown that
there is indeed a modulation of 6-TG activity by MTX.

Materials and Methods

Chemicals.
Industry, CA).

(^C)6-TG was purchased

from

Moravek

Biochemicals (City of

MTX was purchased from Lederle Laboratories (Wayne, NJ).

All

other biochemicals were obtained from Sigma Chemical Co. (St. Louis, MO).
Tissue culture supplies (unless otherwise designated) were obtained from Gibco
Laboratories (Grand Island, NY).
Cells.

L1210 murine leukemia cells were maintained in suspension culture with

Fischer's medium supplemented with 10% heat-inactivated horse serum at 37°C in
a 5% CO2 atmosphere.

All experiments were performed using logarithmically

growing cells (1 to 5 x 10^ cells/ml) which had been initially seeded at 1 to 3 x 10^
cells/ml. Cell density was determined with the use of a model ZBI Coulter Counter
(Coulter Electronics, Hialeah, FL).

-

5

-

Cloning.

Cell viability and drug toxicity were determined using the soft-agar

cloning assay as described by Cadman et al. (3).

Following the indicated single

drug exposure to logarithmically growing cell cultures, the second drug was added
for the specified time.

The drug-containing medium was then removed after

centrifugation at 1000 x g for 5 min at 37°C.

The cells were resuspended in

drug-free medium and recentrifuged as before.

This washing procedure was

repeated twice to remove any extracellular drug before cloning.

Fifty cells

contained in 2 ml of liquified agar 37°C and 3 ml of drug-free Fischer's medium
plus 15% horse serum were pipetted into 10 ml culture tubes.

The tubes were

capped, placed in an upright position and incubated at 37°C in a 5% CC

>2

atmosphere.

The amount of agar in the culture medium was 88 mg/100 ml; the

consistency of this mixture allows cell growth without cell settling.

Cells that

remain viable after drug exposure, as defined by the capability to divide and
produce progeny, will form individual cell colonies after 10 days of incubation. All
clones were counted with an inverted microscope.

Single cells, which can be

visualized in suspension cultures were not observed in the cloning medium after the
10 day incubation, indicating that all viable cells had developed into clones.

The

percent viability is the ratio of clones formed from drug-treated cultures to clones
formed from untreated cultures, multiplied by 100.
L1210 cells in this system was 85 to 90%,

The cloning efficiency of

All data shown are the mean of

triplicate experiments performed on 3 separate occasions.
experiments

was

less

than

10%.

Drug

The variation between

concentrations

were

measured

by

spectrophotometric analysis and drug solutions were prepared the same day of use.
6-TG Metabolism.
180 min.

Cells were exposed to (^C)6-TG for time periods from 1 to

At the specified time, iced saline containing 50 jjM dipyridamole was

added; the cell

pellet

was immediately isolated by centrifugation and then

disrupted by the addition of ice-cold 0.2 N HCIO^. To a tube which contained the
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iced cells (^C)6-TG was added as a control to determine

the amount

of

non-specific radioactivity that would persist during the following DNA and RNA
isolation procedures. The acid-soluble fraction was isolated for HPLC analysis of
intracellular 6-TG nucleotides.
acid-precipitate as follows:

The RNA and DNA were isolated from the

The acid-precipitate was washed twice with iced

0.2 N HCIO^, followed by the addition of 3 ml of 0.3 N NaOH to the washed pellet.
The precipitate was then digested for 1 hour at 37°C.

After cooling on ice, DNA

and protein were precipitated by the addition of 300 pi 5.2 N HCIO^. Five hundred
microliters of the isolated supernatant (containing the RNA fraction) was measured
or radioactivity.

This process was repeated twice to insure complete removal of

all RNA from the remaining precipitate. Following removal of the RNA-containing
supernatant, the precipitate was washed twice with iced 0.2 N HCIO^, resuspended
in 3 ml of 0.5 N HCIO^, and incubated at 70°C for 30 min to solubilize the DNA
fraction.

After cooling on ice, the sample was centrifuged and 500 pM of the

supernatant (containing the DNA fraction) was measured for radioactivity.

The

precipitate was then washed twice with 0.5 N HCIO^ and digested for 1 hour at
70°C in 3 ml of 0.5 N KOH.

Five hundred microliters of

the supernatant

(containing the protein fraction) was neutralized with 1 N HC1 and measured for
radioactivity. Total RNA was quantitated by the orcinol reaction, and total DNA
was quantitated by a standard diphenylamine procedure (6). HPLC analysis of acidsoluble pools was carried out on a SAX anion-exchange column using a 60 min
linear gradient from 0.01 M potassium phosphate (pH 5.7) to 0.75 M potassium
phosphate (pH 4.7).
Cesium Sulfate Gradients.

Incorporation of (^C)6-TG into nucleic acid was

studied using the method of Kufe et al. (7) for quantitative separation of RNA and
DNA by Cs^SO^ equilibrium gradient centrifugation.

After the indicated drug

exposures

saline

to

exponentially

growing

cultures,

-
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iced

containing

50 pM

dipyridamole was added and the cell pellet was isolated by centrifugation.

Cells

were resuspended at a density of 10^ cells/ml in PBS, and 1 ml of the suspension
was added to 2 ml of a solution containing 1.25 mg/ml pronase B (self-digested for
15 min at 37°C), 0.01 M Tris, pH 7.4, 1 mM EDTA, and 0.5% SDS. The mixture was
allowed to digest for 3 hours at 37°C and the total nucleic acid was isolated by 3
cycles of phenolchloroform extraction.

Nucleic acid was precipitated at -20°C

overnight in 2 volumes of absolute ethanol in 0.4 m NaCl.

The pellet isolated by

centrifugation was resuspended in 0.5 ml of 10 nM Tris, pH 8.0, 10 mM EDTA; and
equal volume of formamide was added and the mixture was incubated 15 min at
80°C.

To the mixture was then added 4.14 ml saturated Cs SO^, 3.36 ml 5 mM
2

EDTA; the resulting solution was then centrifuged in a Beckman 50 Tri rotor at
40,000 rpm for at least 60 hours.

The gradients were collected in about 50

fractions of equal volume from the bottom of the tube; the trichloroacetic
acid-precipitable

material

in

each

fraction

was

collected

using

a

MASH

multi-sample processor (Microbiological Associates, Walkersville, MD) and the
radioactivity measured in a Packard Tricarb liquid scintillation spectrometer.

Results

Cytotoxicity.

The cytotoxicity of 6-TG alone and in combinations with MTX was

studied and the results are summarized in Figure 2.

This graph shows the clonal

growth of L1210 mouse leukemia cells following either a 3 hr exposure to 6-TG, a
3 hr exposure simultaneously with 1 pM MTX and 6-TG, or a 3 hr exposure to 6-TG
following a 3 hr pretreatment with 1 pM MTX.

Treatment with 1 pM MTX alone

for 3 hr resulted in a 52% inhibition of clonal growth compared to control, as
depicted in Figure 2 by the horizontal dotted line. Exposure of L1210 cells to 6-TG
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for 3 hr led to a dose-dependent inhibition of clonal growth with an LD^q of
0.8 jjM.

Pretreatment of cells for 3 hr with 1 pM MTX followed by a 3 hr

treatment with 6-TG resulted in a synergistic inhibition of clonal growth at all
concentrations tested; the LD^q for 6-TG was about

10 nM with

1 pM MTX

pretreatment. In contrast, when L1210 cells were exposed simultaneously to 6-TG
and 1 pM MTX for 3 hr, there was no enhancement of 6-TG cytotoxicity.

At low

concentrations of 6-TG (1-10 nM), the inhibition of clonal growth was at best
additive; at higher concentrations of 6-TG (0.1-1 pM), the 1 pM MTX was actually
antagonistic to 6-TG cytotoxicity. Thus, the modulation of 6-TG cytotoxicity can
be either positive or negative.

When 6-TG exposure follows MTX pretreatment,

there appears to be a synergistic enhancement of 6-TG cytotoxicity, but with
concurrent MTX and 6-TG exposure there is an apparent negative modulation or
antagonism of 6-TG cytotoxicity.
Cellular Uptake of 6-TG.

To determine the effect of MTX pretreatment on total

cellular uptake of 6-TG into acid-soluble intracellular pools, cells were exposed to
1 pM (^C)6-TG either with or without pretreatment of the cells with 1 pM MTX;
samples were removed from each culture at times ranging from 1 to 150 min, and
the PCA-soluble radioactivity was determined as described in Methods.

The

results, normalized to the amount of ribose (as RNA) in the acid-precipitable
fraction of each sample, are shown in Figure 3.

The uptake of (^C)6-TG into

L1210 cells is rapid, with apparent equilibration of the acid-soluble pool in less
than five minutes; since the only earlier sampling was at one minute, no statement
can be made comparing the relative rates of 6-TG uptake in MTX-pretreated
versus

control

cells.

There

was

a

small

difference

concentration of 6-TG in acid-soluble intracellular pools.

in

the

steady-state

It is important to keep

in mind that the acid-soluble fraction contains not only free 6-TG but all the small
metabolites of 6-TG, including 6-TG nucleotides.

-
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MTX-pretreated cells had a

steady-state level of about 2.9 pmol 6-TG per pmol cellular RNA ribose, compared
to about 2.5 pmol 6-TG per pmol cellular RNA ribose in control cells.
Metabolism of 6-TG.

As demonstrated above, MTX pretreatment resulted in

increased uptake of 6-TG into the acid-soluble fraction.

The composition of the

acid-soluble pools was further characterized by HPLC analysis as follows.
were exposed to 0.5 pM (

Cells

C)6-TG for 60 min with and without a 3 hr pretreatment

with 1 pM MTX.

The acid-soluble fraction of the cells was isolated and anlayzed

using

described

HPLC

as

in

Methods.

This allowed determination of

the

intracellular levels of free 6-TG as well as the mono-, di-, and triphosphate
metabolites.

These

results are

shown

in

Table 1.

While the intracellular

concentration of free 6-TG was almost identical in MTX-pretreated and control
cultures, there was a substantial difference in the levels of nucleotide metabolites.
TGMP, TGDP, and TGTP levels were all higher in MTX-pretreated cells than in
control cells. The total 6-TG nucleotide concentration, in pmol per 10^ cells, was
2,40 in the MTX-pretreated culture, compared to 1.55 in the control cells.

MTX

pretreatment appears to result in an enhancement of the intracellular conversion
of 6-TG into its nucleotide derivatives.
Incorporation of

6-TG into RNA and DNA.

The effect of MTX on

incorporation into cellular nucleic acids was investigated.

6-TG

Two standard methods

were used to quantitate the relative incorporation of 6-TG into RNA and DNA.
The first method distinguished RNA and DNA incorporation on the basis of
differential hydrolysis by mild alkaline and hot acid conditions.

The second

method, used to confirm the results obtained by the chemical procedure, separated
DNA from RNA using cesium sulfate density gradients (see Methods). Figure 4
shows the time course of incorporation of (

C)6-TG into RNA, with and without a

3 hr pretreatment with 1 pM MTX, using the chemical method.

As expected from

the higher levels of 6-TG nucleotides measured in MTX-pretreated cells, there was

-
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a marked increase in the rate of (
were pretreated with 1 pM MTX.

14

C)6-TG incorporation into RNA when cells

The effect of MTX pretreatment on 6-TG

incorporation into DNA was quite different.

There is a dramatic suppression of

6-TG incorporation into DNA after a 3 hr pretreatment with 1 pM MTX, as shown
in Figure 5.
The results obtained in experiments of similar design which used cesium
sulfate equilibrium density gradients as the technique for separating RNA from
DNA are shown in Figures 6 and 7.

The results are qualitatively similar to those

obtained by the differential hydrolysis procedure: MTX pretreatment at 1 pM for
1 hr leads to enhanced incorporation of (

14

C)6-TG into RNA while suppressing

incorporation of (^C)6-TG into DNA. While there are quantitative differences in
the results which are probably attributable to the inherent differences in the
technique, there is good qualitative agreement.

This lends independent support to

the conclusions drawn using the other technique.

Discussion

These experiments have demonstrated that MTX can modulate the cytotoxic
activity of 6-TG in mouse L1210 cells, and that this modulation depends on the
schedule of drug administration.

By characterizing some of the biochemical

interactions of MTX and 6-TG in L1210 cells, these studies provide evidence for
the metabolic basis of the drug interaction and suggest a mechanism to explain the
synergistic cytotoxicity found under some conditions.
Pretreatment of L1210 cells with MTX synergistically enhanced the cytotoxic
activity of 6-TG as measured by the soft-agar cloning assay.

The same MTX

pretreatment was found to result in somewhat increased uptake of 6-TG into cells,
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increased conversion of free 6-TG to 6-TG nucleotides, and markedly increased
incorporation of 6-TG into RNA.

Simultaneous treatment with MTX and 6-TG

resulted in an antagnostic interaction between the drugs.

An analogy can be drawn

between these results and those already reported describing the interaction
between MTX and 5-FU (3,4,8).

The cytotoxicity of 5-FU is synergistically

enhanced by MTX pretreatment of murine LI210, human colorectal tumor line
HCT-8, and human breast carcinoma line 47-DN (3,8); in L1210 cells, simultaneous
MTX and FUra treatment antagonizes the FUra cytotoxicity. It was shown (4) that
the enhanced FUra toxicity in

MTX-pretreated

cells was due to increased

intracellular levels of PRPP, the co-substrate of orotate-phosphoribosyltransferase
which activates FUra in the cells; the increased availability of PRPP leads to
enhanced activation of FUra to FUra-nucleotides and thus greater cytotoxicity. A
3 hr treatment wtih 1 pM MTX, the regimen used in these experiments, was found
to result in a 4- to 5-fold expansion of PRPP pool size; this was associated with a
marked increase in the level of FUra-nucleotides and in the rate of FUra
incorporation into RNA.

These experiments with 6-TG are less complete in a

number of ways, but nevertheless they demonstrate important points.

The effect

of a varying MTX dose on cytotoxicity or on the various biochemical parameters
was not examined; we cannot say that the dose of 1 pM was optimal or that the
pretreatment

interval

of

3 hr

was

ideal

for

modulation

of

6-TG

activity.

Therefore, a dose-response relationship has not been established between MTX
pretreatment (thus by inference cellular PRPP levels) and cellular 6-TG nucleotide
levels or 6-TG incorporation into RNA.

Noteworthy, however, is the recent

report (9) of other work in this laboratory that a 3 hr exposure of L1210 cells to
1 uM MTX increased intracellular PRPP levels from 4.1 to 125 ngm/10^ cells. This
demonstrates a correlation between elevated

PRPP levels and the increased

activation of 6-TG, reported here, following pretreatment for 3 hrs with 1 pM

-
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MTX.

In the present report, 6-TG concentration was held constant in all

experiments

except

the

cytotoxicity assays, so the effect of varying 6-TG

concentration or treatment interval is not known. These provisos notwithstanding,
we have demonstrated schedule-dependent modulation of 6-TG activity by MTX
and have provided strong evidence that the mechanism of modulation is analogous
to that more thoroughly worked out for the MTX-FUra interaction.
It is less clear what is the biochemical basis for 6-TG cytotoxicity.

It has

been reported (5) that the toxic effects ot 6-TG derive from its incorporation into
cellular DNA. The results of the present study, while not conclusive, suggest that
6-TG incorporation into RNA, rather than DNA, is the most important event
contributing to drug toxicity. Both the selective hydrolysis and the cesium sulfate
gradient techniques gave the result that, under conditions where MTX potentiates
the cytotoxic effects of 6-TG, there is a marked increase in the rate of
incorporation of 6-TG into RNA and a dramatic suppression of 6-TG incorporation
into DNA. It is possible that incorporation of abnormal bases into RNA could cause
alterations in RNA function.

This type of effect has been observed with other

antimetabolites such as 5-azacytidine and FUra (10,11), though the contribution of
6-TG incorporation into RNA to cytotoxicity has not been previously established.
While the increased 6-TG incorporation into RNA is understandable in terms of
elevated levels of 6-TG nucleotides, the decreased incorporation of 6-TG into DNA
is not as simple to explain.

The suppression may, at least, be partly due to the

inhibition of DNA synthesis caused by MTX; only direct measurements of the rate
of DNA synthesis will reveal whether the differential rate of 6-TG incorporation
into DNA is altered by MTX treatment. It is also interesting to note that 6-TGRP
has

been

reported

biosynthesis (2).

to

inhibit

several

enzymes

involved

in

de

novo

purine

This could provide an explanation not only for the decreased

incorporation of 6-TG into DNA but also for a synergistic cytotoxicity with MTX

-
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and 6-TG. The present experiments have not addressed this issue, and further work
will be needed to clarify the relative contributions of the various effects of 6-TG
to the ultimate lethality of the drug treatment.
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Table 1
Metabolism of 6-TG to 6-TG-Nucleotides

L1210 cells both with and without pre-exposure to 1 pM MTX were exposed
to 0.5 pM (

14

C)6-TG for 60 min, and the cellular levels of 6-TG and 6-TG-

nucleotides determined as described under "Materials and Methods."^

Drug

6-TG

TGMP

pmol/10^ cells
TGDP

TGTP

Total
Nucleotide

6-TG

3.43

0.90

0.28

0.37

1.55

MTX-+6-TG

3.36

1.60

0.32

0.48

2.40

Results are representative of 4 separate experiments.
between experiments was less than ten percent.
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The variation

Figure Legends

Fig. 1

The

effect

of

methotrexate

(MTX)

on

purine

synthesis

and

5-fluorouracil (5-FU) metabolism.

Because of the depleted folates,

purine

the

synthesis

ceases

allowing

phosphoribosylpyrophosphate

(PRPP), which would have been utilized for de novo purine biosynthesis,
to be used for the conversion of 5-FU to 5-FUMP.

Fig. 2

Cytotoxicity of

6-TG

in

L1210 cells.

L1210 leukemia cells were

exposed for 3 hr to 6-TG either alone (•), simultaneously with 1 pM
MTX (A), or following a

3 hr

pre-epxosure to

percent clone growth determined.

1 pM MTX (o), and

Clonal growth of cells exposed to

1 pM MTX alone for 3 hr is illustrated by the dotted line.

Results

represent the mean of 4 separate experiments.

Fig. 3

Accumulation of 6-TG in intracellular acid-soluble pools.

L1210 cells

were exposed to 1 pM (^C)6-TG for 1 to 180 minutes and the acidsoluble intracellular radioactivity measured.

Cells were exposed either

to 6-TG alone (•) or 6-TG following a 3 hr pretreatment with 1 pM
MTX (o). Results are representative of 4 separate experiments.

Fig. 4

Incorporation of 6-TG into RNA: selective hydrolysis assay.

L1210

cells were exposed to 1 pM (^C)6-TG for 1 to 180 minutes and alkalihydrolyzable, PCA-precipitable radioactivity determined (see Methods).
Cells were exposed to 6-TG alone (•) or to 6-TG following a 3 hr
pretreatment with

1 pM

MTX (o).

separate experiments.
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Results are representative of 4

Fig. 5

Incorporation of 6-TG into DNA: selective hydrolysis technique.

LI210

cells were exposed to 1 pM (*^C)6-TG for 1 to 180 minutes, and PCAprecipitable,

hot

acid-hydrolyzable

radioactivity

determined

(see

Methods). Cells were exposed to 6-TG alone (•) or to 6-TG following a
3 hr pretreatment with 1 pM MTX (o).

Results are representative of 4

separate experiments.

Fig. 6

Incorporation of 6-TG into RNA: cesium sulfate gradient technique.
L1210 cells were exposed to 1 pM (^C)6-TG for 10 to 180 minutes, the
nucleic acid isolated and separated into DNA and RNA fractions by
cesium sulfate density gradient centrifugation, and the corresponding
radioactivity determined (see Methods).

Cells were exposed either to

6-TG alone (•) or to 6-TG following a 3 hr pretreatment with 1 pM
MTX (o).

Fig. 7

Incorporation of 6-TG into DNA: cesium sulfate gradient technique.
L1210 cells were exposed to 1 pM (^C)6-TG for 10 to 180 minutes, the
nucleic acid isolated and separated into DNA and RNA fractions by
cesium sulfate density gradient centrifugation, and the corresponding
radioactivity determined (see Methods).

Cells were exposed to either

6-TG alone (#) or to 6-TG following a 3 hr pretreatment with
MTX (o).
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